Mark Lynch

Mark Lynch

Bristol-Myers Squibb Co. - New York / United States
Others
AD Scientific Index ID: 4375838
-
person_outline Mark Lynch's MOST POPULAR ARTICLES
1-) Nivolumab for recurrent squamous-cell carcinoma of the head and neck New England Journal of Medicine 375 (19), 1856-1867, 2016
2-) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 Cancer research 66 (24), 11851-11858, 2006
3-) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling Molecular cancer therapeutics 7 (10), 3129-3140, 2008
4-) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5L Liu, Y Cao, C Chen, X Zhang, A McNabola, D Wilkie, S Wilhelm, ...Cancer research 66 (24), 11851-11858, 200618392006
5-) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signalingSM Wilhelm, L Adnane, P Newell, A Villanueva, JM Llovet, M LynchMolecular cancer therapeutics 7 (10), 3129-3140, 200817172008